2) Our expert author is Vijaya Raj Bhatt, @VijayaRBhatt1 MBBS, MS, Section Leader, Malignant Hematology, @UNMCHemeOnc @UNMC_IM @NebraskaMed.#onctwitter #FOAMed @MedTweetorials #hemetwitter #Hematologist #Oncologists #MedEd #CancerCare @NCCN @ASCO @ASH_hematology pic.twitter.com/5FddiACSUd
— @onc_ce (@onc_ce) April 18, 2023
4) Myelodysplastic syndrome #MDS #MDSsm is a blood #cancer that can be indolent or rapidly fatal like acute #leukemia #AMLsm.
— @onc_ce (@onc_ce) April 18, 2023
❓What role can primary care physicians #PCPs play in timely diagnosis, referral, and treatment of patients with low-risk MDS?
5b) … and show variable rates of transformation to acute myeloid leukemia #AML or bone marrow failure. Let's start with a knowledge check. Which of the following is the most common isolated #cytopenia associated with #MDS?
— @onc_ce (@onc_ce) April 18, 2023
6a) When should a #PCP suspect #MDS? Here are clues:
— @onc_ce (@onc_ce) April 18, 2023
?Older age: MDS is uncommon in people < 40-50ys
?Prior exposure to chemotx or radiation for other conditions ⬆️risk. Exposure to certain chemicals eg #benzene in ? exhaust, industrial emissions, ?) also associated with MDS pic.twitter.com/Bm2RVpPYgx
6c)
— @onc_ce (@onc_ce) April 18, 2023
?Pts often present w/ normocytic or macrocytic anemia, #bicytopenia or #pancytopenia. Isolated thrombocytopenia or neutropenia are uncommon presentation. Many adults can be asymptomatic at presentation with #cytopenias being detected during routine blood tests.
7a) So how should #PCP approach an adult presenting w/ ⬇️ blood count(s)?
— @onc_ce (@onc_ce) April 18, 2023
1⃣Dx of low-risk #MDS req's exclusion of other causes. DDx inc's: nutritional deficiency (vit B12, #folic acid, #copper), exposure to drugs/toxins inc excess ?, #marrow suppression from acute illness.
8) When should a patient be referred to #hematology?
— @onc_ce (@onc_ce) April 18, 2023
?A patient who has cytopenia(s) that is unexplained and sustained or severe requires referral.
?The presence of dysplastic cells or blasts in peripheral smear require referral.
9b) The correct answer is NO. #Dysplastic cells may also be noted in many nonclonal diseases such as infections, autoimmune disorders, nutritional deficiencies, drugs, or toxin exposure.
— @onc_ce (@onc_ce) April 18, 2023
See ? https://t.co/DTrUAMDtyk
11a) What are challenges assoc'd w/ dx of low-risk #MDS?
— @onc_ce (@onc_ce) April 18, 2023
1⃣ Only #dysplasia or #cytogenetic or molecular abnormalities does NOT establish dx of MDS.
2⃣ Dysplasia alone may be seen in #marrow #biopsy after recovery from non-malignant causes of marrow suppression . . .
11c)
— @onc_ce (@onc_ce) April 18, 2023
3⃣Mutations can be present in healthy people (clonal hematopoiesis of indeterminate potential or #CHIP) or those with cytopenias without dysplasia or increased blasts (clonal cytopenia of undetermined significance or #CCUS). pic.twitter.com/nz7icCPCfX
12a) While a patient is awaiting a #hematology visit, a #PCP can provide general information regarding prognosis and treatment approaches.
— @onc_ce (@onc_ce) April 18, 2023
12c) Multiple validations of this model:
— @onc_ce (@onc_ce) April 18, 2023
?https://t.co/1TmhdWnIHg
?https://t.co/1b4IGGbeG4
?https://t.co/dsenVeXyf1 pic.twitter.com/7kxU826ig9
13b) Prior exposure to #chemotherapy/#radiation, #comorbidity burden and overall #fitness also influence response to treatment and treatment tolerance.
— @onc_ce (@onc_ce) April 18, 2023
14b) It's FALSE: See the following figure from ? https://t.co/TF3KIhI7cj by @DavidSteensma pic.twitter.com/UqqBxvbB3z
— @onc_ce (@onc_ce) April 18, 2023
15b)
— @onc_ce (@onc_ce) April 18, 2023
Lower-risk #MDS:
? Improve quality of life
? Reduce symptom burden
Higher-risk MDS:
?Prolong life expectancy
?Delay the risk of #leukemia
?Asymptomatic patients with #MDS with mild #cytopenias do not require specific treatment.
16b)
— @onc_ce (@onc_ce) April 18, 2023
?Vaccinations as advised by #ACIP guidelines such as #COVID-19 vaccines, #pneumococcal vaccines, #shingles vaccines, & annual #influenza vaccine can reduce the risk of infections. pic.twitter.com/J5hOFejQ2f
17a) What are some of the tx options for low-risk #MDS?
— @onc_ce (@onc_ce) April 18, 2023
Medicines to treat anemia:
?#ESAs: most effective in a patient with low transfusion need (<2/month) & low erythropoietin level (<500U/L)
?#Luspatercept: effective in a patient with ringed #sideroblast or #SF3B1 mutation
17c) Other treatment options that may have role in select patients with lower-risk #MDS include immunosuppressive agents such as anti-thymocyte globulin, thrombopoietin mimetics and hypomethylating agent such as azacitidine or decitabine.
— @onc_ce (@onc_ce) April 18, 2023
18) And that's it! You just earned 0.5hr ?CE/#CME! Point your ?️ to https://t.co/RTor16zHQK and claim your certificate!
— @onc_ce (@onc_ce) April 18, 2023
I am @VijayaRBhatt1 and I thank you for joining us!
